Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma

BACKGROUND: Primary adenosquamous carcinoma (ASC) of the lung is a rare and aggressive disease and limited information is available on the efficacy of immune checkpoint inhibitors (ICIs) for this disease. Here, we evaluated the expression status of programmed death-1 ligand 1 (PD-L1) and efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jingwen, Xiang, Jing, Hao, Yue, Si, Jinfei, Gu, Xiaodong, Xu, Manyi, Song, Zhengbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992578/
https://www.ncbi.nlm.nih.gov/pubmed/36910045
http://dx.doi.org/10.21037/jtd-22-1011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992578/
https://www.ncbi.nlm.nih.gov/pubmed/36910045
http://dx.doi.org/10.21037/jtd-22-1011

Ejemplares similares